Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Kevin Conroy appointed to Abbott’s Board on April 24, 2026.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Kevin Conroy appointed to Abbott’s Board on April 24, 2026
- Shareholders approved the 2026 Incentive Stock Program, replacing the 2017 Program
- Program authorizes up to 140,000,000 Abbott common shares, subject to specified adjustments
- Ten-year program permits equity awards to employees, subsidiaries’ employees, and non-employee directors
- Potential dilution and compensation expense relevant to shareholder returns and governance oversight
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Board expanded from 12 to 13 directors effective April 24, 2026, increasing governance capacity
- All 12 director nominees elected, though CEO Robert B. Ford received relatively higher opposition at 72.6M shares
- Executive compensation approved on advisory basis with 90.35% support, signaling strong shareholder alignment
- 2026 Incentive Stock Program approved with 95.82% support, enabling continued equity-based compensation
- Non-U.S. Employee Stock Purchase Plan approved with 99.33% support; Ernst & Young ratified as auditor with 1.50B votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.